A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice

A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice

Author Gentil, Fernanda Google Scholar
Bargieri, Daniel Y. Autor UNIFESP Google Scholar
Leite, Juliana A. Google Scholar
Francoso, Katia S. Google Scholar
Patricio, Mariana B. M. Google Scholar
Espindola, Noeli M. Google Scholar
Vaz, Adelaide J. Google Scholar
Palatnik-de-Sousa, Clarisa B. Google Scholar
Rodrigues, Mauricio M. Autor UNIFESP Google Scholar
Costa, Fabio Trindade Maranhão Autor UNIFESP Google Scholar
Soares, Irene S. Google Scholar
Institution Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Universidade Estadual de Campinas (UNICAMP)
Universidade Federal do Rio de Janeiro (UFRJ)
Abstract The Apical Membrane Antigen 1 (AMA-1) is considered a promising candidate for development of a malaria vaccine against asexual stages of Plasmodium. We recently identified domain II (DII) of Plasmodium vivax AMA-1 (PvAMA-1) as a highly immunogenic region recognised by IgG antibodies present in many individuals during patent infection with P. vivax. the present study was designed to evaluate the immunogenic properties of a bacterial recombinant protein containing PvAMA-1 DII. To accomplish this, the recombinant protein was administered to mice in the presence of each of the following six adjuvants: Complete/Incomplete Freund's Adjuvant (CFA/IFA), aluminium hydroxide (Alum), Quil A, QS21 saponin, CpG-ODN 1826 and TiterMax. We found that recombinant DII was highly immunogenic in BALB/c mice when administered in the presence of any of the tested adjuvants. Importantly, we show that DII-specific antibodies recognised the native AMA-1 protein expressed on the surface of P. vivax merozoites isolated from the blood of infected patients. These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria. (C) 2010 Elsevier B.V. All rights reserved.
Keywords Malaria
Plasmodium vivax
Recombinant vaccine
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
The National Institute for Vaccine Development and Technology
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Grant number FAPESP: 2006/02832-0
Date 2010-08-31
Published in Vaccine. Oxford: Elsevier B.V., v. 28, n. 38, p. 6183-6190, 2010.
ISSN 0264-410X (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 6183-6190
Origin http://dx.doi.org/10.1016/j.vaccine.2010.07.017
Access rights Closed access
Type Article
Web of Science ID WOS:000282150700011
URI http://repositorio.unifesp.br/handle/11600/32830

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account